

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Avigen, Inc.	09/12/2006

RECEIVING PARTY DATA

Name:	Genzyme Corporation
Street Address:	500 Kendall Street
City:	Cambridge
State/Country:	MASSACHUSETTS
Postal Code:	02142

PROPERTY NUMBERS Total: 16

Property Type	Number
Patent Number:	5858351
Application Number:	09226989
Application Number:	10092454
Patent Number:	5962213
Patent Number:	5846528
Patent Number:	6325998
Patent Number:	6211163
Patent Number:	6391858
Patent Number:	6335011
Patent Number:	6610290
Application Number:	10445088
Application Number:	09969327
Application Number:	11305629
Application Number:	11303896
PCT Number:	US9700895

PATENT

500150576

REEL: 018239 FRAME: 0292

CH \$640.00 5858351

PCT Number:

US9700980

**CORRESPONDENCE DATA**

Fax Number: (508)872-5415

*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

Phone: 5082702551

Email: taryn.antalek@genzyme.com

Correspondent Name: Taryn Antalek

Address Line 1: 15 Pleasant Street Connector

Address Line 4: Framingham, MASSACHUSETTS 01701-9322

ATTORNEY DOCKET NUMBER:

1005

NAME OF SUBMITTER:

Taryn Antalek

Total Attachments: 3

source=Assignment#page1.tif

source=Assignment#page2.tif

source=Assignment#page3.tif

## ACKNOWLEDGEMENT OF ASSIGNMENT

Avigen, Inc., a Delaware corporation ("Avigen") was heretofore the owner of the entire right, title and interest in and to the following:

- 1) "Methods for delivering DNA to muscle cells using recombinant adeno- associated virus vector" filed on January 18, 1996 in the United States Patent and Trademark Office having Serial No. 08/588,355; now issued as United States Letter Patent No. 5,858,351 on January 12, 1999;
- 2) "Methods for delivering DNA to muscle cells using recombinant adeno- associated virus vector" filed on January 7, 1999 in the United States Patent and Trademark Office having Serial No. 09/226,989; now abandoned;
- 3) "Methods for delivering DNA to muscle cells using recombinant adeno- associated virus vector" filed on March 5, 2002 in the United States Patent and Trademark Office having Serial No. 10/092,454; now pending;
- 4) "Adeno-associated virus vectors comprising a gene encoding a lysosomal enzyme" filed on January 16, 1997 in the United States Patent and Trademark Office having Serial No. 08/784,757; now issued as United States Letter Patent No. 5,962,213 on October 5, 1999;
- 5) "Treating anemia using recombinant adeno-associated virus virions comprising and EPO DNA sequence" filed on January 16, 1997 in the United States Patent and Trademark Office having Serial No. 08/787,750; now issued as United States Letter Patent No. 5,846,528 on December 8, 1998;
- 6) "Methods of treating disease using recombinant adeno-associated virus virions administered to muscle" filed on December 4, 1998 in the United States Patent and Trademark Office having Serial No. 09/205,337; now issued as United States Letter Patent No. 6,325,998 on December 4, 2001;
- 7) "Methods for delivering DNA to the bloodstream using recombinant adeno-associated virus vectors" filed on May 10, 1999 in the United States Patent and Trademark Office having Serial No. 09/309,042; now issued as United States Letter Patent No. 6,211,163 on April 3, 2001;
- 8) "Methods for delivering DNA to the bloodstream using recombinant adeno-associated virus vectors" filed on January 4, 2001 in the United States Patent and Trademark Office having Serial No. 09/755,734; now issued as United States Letter Patent No. 6,391,858 on May 21, 2002;
- 9) "Methods for delivering DNA to the bloodstream using recombinant adeno-associated virus vectors" filed March 5, 2002 in the United States Patent and Trademark Office having Serial No. 10/092,454; now pending;
- 10) "Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions to treat lysosomal storage disease" filed on September 28, 1999 in the United States Patent and Trademark Office having Serial No. 09/406,362; now issued as United States Letter Patent No. 6,335,011 on January 1, 2002;

11) "Adeno-associated virus vectors for the treatment of a cardiomyopathy" filed on October 1, 2001 in the United States Patent and Trademark Office having Serial No. 09/969,204; now issued as United States Letter Patent No. 6,610,290 on August 26, 2003;

12) "Adeno-associated virus vectors for the treatment of a cardiomyopathy" filed on May 23, 2003 in the United States Patent and Trademark Office having Serial No. 10/445,088, now abandoned;

13) "Methods of treating anemia using recombinant adeno-associated virus virions" filed on October 1, 2001 in the United States Patent and Trademark Office having Serial No. 09/969,327; now abandoned;

14) "Methods of treating anemia using recombinant adeno-associated virus virions" filed on December 15, 2005 in the United States Patent and Trademark Office having Serial No. 11/305,629; now pending;

15) "Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions" filed on December 15, 2005, in the United States Patent and Trademark Office having Serial No. 11/303,896, now pending;

16) "Methods for Delivering DNA to Muscle Cells Using rAAV Virions" filed on January 17, 1997 according to the Patent Cooperation Treaty as Serial No. PCT/US97/00895; now abandoned;

17) "Compositions for Treating Anemia" filed on January 17, 1997 according to the Patent Cooperation Treaty as Serial No. PCT/US97/00980; now abandoned;

(together with all other patent applications claiming priority thereto, patents issuing in any of the foregoing and all re-examinations, re-issues and extensions thereof, the "Assigned Patents").

By prior assignment pursuant to that certain Assignment Agreement executed between Avigen and Genzyme Corporation, a Massachusetts corporation ("Genzyme") on December 19, 2005 ("Avigen-Genzyme Assignment Agreement"), Avigen transferred, assigned, and conveyed to Genzyme, the entire right, title and interest in and to the Assigned Patents, subject to Avigen's rights under the Avigen-Genzyme Assignment Agreement (including without limitation rights to payments and reversionary rights that under certain circumstances cause the entire right, title, and interest in and to the Assigned Patents to revert to Avigen all more fully described in the Avigen-Genzyme Assignment Agreement).

NOW THEREFORE, Avigen hereby acknowledges that pursuant to and subject to the terms and conditions of the Avigen-Genzyme Assignment Agreement, it has heretofore transferred, assigned and conveyed to Genzyme the entire right, title and interest to the Assigned Patents, subject to Avigen's rights described above.

Avigen hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and all of foreign countries to issue any Letters Patent granted among the Assigned Patents (whether on the foregoing explicitly identified by number applications or on any subsequently filed division, continuation, continuation in part, reexamination or reissue application), to Genzyme, its successors and assigns.

IN TESTIMONY WHEREOF, the undersigned has executed this instrument on the 12<sup>th</sup> day of September 2006.

By: M. Christa Thomson

Print name: M. CHRISTINA THOMSON

Title: VICE PRESIDENT, CORPORATE COUNSEL

M. CHRISTINA THOMSON  
VICE PRESIDENT,  
CORPORATE COUNSEL

State of California )

County of Alameda )

ss.

On Sept. 12, 2006 before me, Lois E. Miller, Notary Public personally appeared M. Christina Thomson personally known to me or proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is (are) subscribed to the within instrument and acknowledge to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

Lois E. Miller (Notary signature)

(Notary Seal)

